Antitrust and unfair competition laws exist to ensure that businesses compete against each other, and Girard Gibbs prosecutes cases to hold companies accountable for violating those laws.
We represent companies and consumers in class action lawsuits against corporations around the world that engage in price fixing and other anti-competitive practices.
Our Leadership in Antitrust Litigation
Our firm is currently serving in a leadership capacity in several nationwide cases against some of the world’s largest companies, including:
In re Lidoderm Antitrust Litigation (N.D. Cal.)
The firm serves as Interim Co-Lead Counsel for the end-payor plaintiffs in this multidistrict litigation alleging that the brand and generic manufacturers of the drug Lidoderm, a patch used to alleviate pain associated with the after effects of shingles, entered into an unlawful agreement to delay the release of generic Lidoderm for up to thirteen months.
In re Capacitors Antitrust Litigation (N.D. Cal.)
Girard Gibbs represents direct purchasers of capacitors in this multidistrict litigation alleging that some of the world’s largest electronics manufacturers, including Panasonic, Sanyo, and Hitachi, conspired to fix the prices of capacitors. The firm is playing an active role in directing discovery for the direct purchaser plaintiffs.
In re Nexium Antitrust Litigation (D. Mass.)
Girard Gibbs took a lead role in directing discovery on behalf of the end-payor plaintiffs in this “pay-for-delay” litigation, and serves on the Executive Committee.
In re Solodyn (Minocycline Hydrochloride) Antitrust Litigation (D. Mass.)
The firm serves on the Executive Committee representing end-payor plaintiffs in this multidistrict class action alleging that Medicis Pharmaceutical Corporation entered into a series of unlawful “pay-for-delay” agreements with generic manufacturers to prevent competition for the drug Solodyn.
In re Aggrenox Antitrust Litigation (D. Conn.)
Girard Gibbs serves on the Executive Committee for end-payor plaintiffs in this multidistrict class action alleging brand and generic manufacturers of the drug Aggrenox entered into an unlawful agreement to delay the entry of a less-expensive generic version of Aggrenox.
In re Niaspan Antitrust Litigation (E.D. Pa.)
The firm serves on the Executive Committee for end-payor plaintiffs in this multidistrict class action alleging that brand and generic manufacturers delayed the release of a generic version of the drug Niaspan for up to eight years through an unlawful “pay-for-delay” agreement.
In re Aluminum Warehousing Antitrust Litigation (S.D. N.Y.)
Girard Gibbs was appointed as Interim Co-Lead Counsel for commercial end user plaintiffs in this multidistrict litigation alleging that defendants conspired to limit the supply, and increase the price of, aluminum throughout the United States.
Current Antitrust Cases
- In re High-Tech Employee Antitrust Litigation (N.D. Cal.)
Girard Gibbs represents a class representative who played an instrumental role in negotiating a $90.5 million increase to a $324.5 million that had previously been rejected by the Court presiding over the action. The Court recently granted preliminarily approval of the new $415,000,000 settlement.
- In re Actos End-Payor Antitrust Litigation (S.D. N.Y.)
The firm represents indirect purchasers in this multidistrict class action litigation alleging that the brand and generic manufacturers of the blockbuster drug Actos entered into anticompetitive “pay-for-delay” agreements.
- In re Transpacific Passenger Air Transportation Antitrust Litigation (N.D. Cal.)
Girard Gibbs represents consumers in this multidistrict litigation alleging a long-running conspiracy to fix the prices of international flights involving at least one flight segment between the United States and Asia. To date, the plaintiffs in the case have entered settlement agreements with eight defendants totaling $39,000,000, with the litigation proceeding against the remaining defendants.
|TFT-LCD (Flat Panel) Antitrust Litigation||Over $470 million for direct purchasers of thin film transistor liquid crystal display products.|
|Natural Gas Antitrust Litigation I, II, II, IV||$160 million settlement from gas companies for alleged manipulation of California’s natural gas market|